Drug Trial Radar · NCT06967519
OPTImizing Malaria And HIV Treatment in a Shifting Landscape in Africa
Last checked: Nov 20, 2026Latest source record: Feb 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
380
Planned (sponsor's estimate)
Start
Dec 18, 2025
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Yale UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- First posted
- May 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 5 years, up to 17 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A longitudinal study with four parallel cohorts with each participant followed for 2 years: two cohorts in Busia (high malaria transmission site) and two cohorts in Kampala (low malaria transmission). Each site will have a cohort of children living with HIV (CLHIV) and HIV- uninfected children and will be age-matched, enrolled in parallel, and followed for two years. All children will be enrolled without malaria infection, as determined by a negative blood smear at baseline.
Conditions
- Malaria
- Hiv
Interventions
Artemether-lumefantrine (AL)Drug
Participants will receive the dispersible formulation of AL with contains 20 mg artemether, 120 mg of lumefantrine
artesunate-amodiaquine (AS-AQ)Drug
Children will receive the tablet formulations of Artesunate Amodiaquine using weight based dosing
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Body Mass Index (BMI)Time frame: baseline and 2 years
- Drug pharmacokinetic (PK) exposureTime frame: baseline up to 2 years
- Drug pharmacokinetic exposureTime frame: baseline up to 2 years
- Recurrence rate of malariaTime frame: 28 days and 42 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Baylor- Uganda
Kampala, Uganda · Recruiting
Infectious Disease Research Collaboration (IDRC)
Kampala, Uganda · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.